The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

This report provides all the information you require to better understand Cephalon and its partnering interests and activities over the past seven years. Read the full story

Cephalon, Inc. is an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd, is , is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Acino will acquire Cephalon’s combined Middle East and African business for a total consideration of approximately EUR 80 million. Read the full story

Teva states in a notice to the US Securities and Exchange Commission (SEC) that if Cephalon cancels its acquisition by Teva, it will pay a fine of 4% of the $6.8 billion deal - or $275 million. Read the full story

Cephalon have accepted a bid from Teva which values the company at $6.8 billion, some $1.1 billion more than the Valeant offer of several weeks ago. Read the full story

Now that Teva Pharmaceutical Industries has snatched Cephalon, what's next for would-be suitor Valeant Pharmaceuticals? Read the full story

Welcome to the April 2011 edition of Current Agreements Deals Update. Read the full story

Valeant Pharmaceuticals' $5.7 billion bid for Cephalon may spawn a series of copycat deals, Reuters reports... Read the full story